

Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective?

Smith, Alison; Hall, Peter; Hulme, Claire; Dunn, Janet; Joy, Rahman; McConkey, Christopher; Mehanna, Hesham

License:

None: All rights reserved

Document Version

Other version

Citation for published version (Harvard):

Smith, A, Hall, P, Hulme, C, Dunn, J, Joy, R, McConkey, C & Mehanna, H 2015, 'Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? results from a UK non-inferiority phase III randomized trial', 2015 ASCO Annual Meeting, Chicago, United States, 29/05/15 - 2/06/15.

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

PET-Neck late breaking abstract

Authors: Smith A. F., Hall P. S., Hulme C., Dunn J., Rahman J. K., McConkey C., Mehanna H.

Title: Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial.

Background: Despite ongoing controversy, planned node dissection (ND) remains a common treatment strategy after radical chemoradiotherapy (CRT) for locally advanced nodal metastases in patients with HNSCC. Accurate detection of persistent disease using combined Positron Emission and Computerised Tomography (PET-CT) could reduce unnecessary and expensive node dissections (ND) in low-risk patients and potentially improve overall outcomes.

Methods: 564 patients with N2/N3 oropharyngeal, laryngeal, oral, hypopharyngeal or occult HNSCC were randomized (1:1) to receive either planned ND (before or after CRT), or PET-CT surveillance (CRT followed by PET-CT, with ND administered if incomplete response in the neck nodes). To accurately inform reimbursement decisions, individual patient data from the trial was used to assess within-trial (2-year) cost-effectiveness of PET-CT surveillance versus planned ND from an NHS secondary care perspective. Health benefit was measured using quality-adjusted life-years (QALYs) and costs are reported in 2015 GBP. Probabilistic analysis was conducted using bootstrap methods.

Results: PET-CT surveillance was cost-effective over the trial period, producing an average per-person cost saving of £1,415 (95% CI: -607 to -2,218) and a health gain of 0.07 QALYs (95% CI: -0.04 to 0.19) compared to planned ND. The average cost was £12,127 (95% CI: 11,601 to 12,686) for PET-CT surveillance vs. £13,542 (95% CI: 12,968 to 14,131) for planned ND; the average QALYs were 1.26 (95% CI: 1.18 to 1.34) vs. 1.19 (95% CI: 1.10 to 1.27). At a £20,000 per QALY threshold, the probability that PET-CT was the cheapest, most effective and most cost-effective strategy was 99%, 91%, and 98%, respectively. Expanding the analysis to include additional NHS, personal social services and societal costs increased the expected costs for each arm but did not alter the overall cost-effectiveness of PET-CT surveillance.

Conclusions: Results of the economic evaluation indicate that PET-CT surveillance is cost-effective over a short time horizon.